SLDB Solid Biosciences Inc

Solid Biosciences to Present at Upcoming Investor Conferences

Solid Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Technology Officer, and Cathryn Clary, MD, MBA, Acting Chief Medical Officer, will participate at the following two upcoming investor conferences:

  • SVB Leerink 10th Annual Global Healthcare Conference

    Fireside chat on Wednesday, February 24, 2021 at 1:40 p.m. ET.
  • Barclays Global Healthcare Conference

    Fireside chat on Thursday, March 11, 2021 at 9:45 a.m. ET.

A live webcast of these presentations will be available on the Company’s investor relations website, under the Events page accessible here: . A replay will be available on the Company's website following the event.

About Solid Biosciences

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit .

Investor Contact:

David Carey

FINN Partners

212-867-1768

Media Contact:

Erich Sandoval

FINN Partners

917-497-2867



EN
17/02/2021

Underlying

SLDBSolid Biosciences Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Solid Biosciences Inc

 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences to Participate at Upcoming Investor Conferences CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 25th Annual Needham Virtual Healthcare ConferenceBo Cumbo, President and CEO, will participate in a virtual fireside chat on Tuesday, April 14, 2026, at 2:15 pm ET.A live webcast of the presentation will be available on the Events page...

April 7, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1...

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in muscle integrity, including stabilization and improvement in cardiac function (LVEF) observed after treatment with SGT-003 - - SGT-003 continued to demonstrate an encouraging safety profile and has been generally well tolerated in the 40 participants dosed as...

March 11, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Announces Oversubscribed $240 Million Private Placem...

Solid Biosciences Announces Oversubscribed $240 Million Private Placement CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $240 million private placement, before deducting placement agent fees and offering expenses, which is expected to close on or about March 9, 2026, subject to the satisfacti...

March 6, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Present at the 2026 Muscular Dystrophy Associatio...

Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its next-generation investigational gene therapy for Duchenne muscular dystrophy, and SGT-212, its dual-route investigational gene therapy for Friedreich’s ataxia (FA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Confe...

March 6, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 17,600 restricted stock units (“RSUs”) to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s c...

March 2, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch